Vol 18, No 3 (2022)
Commentary
Published online: 2022-03-03
Commentary to Targeted therapy for advanced cutaneous melanoma
Oncol Clin Pract 2022;18(3):208-209.
Abstract
Not available
References
- Rutkowski P, Mandala M. (ed.). New Therapies in Advanced Cutaneous Malignancies. Springer Nature 2021.
- Rutkowski P, Wysocki PJ, Kozak K, et al. xpert recommendations on diagnostic-therapeutic management of melanoma patients. Oncol Clin Pract. .
- Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013; 19(5): 1225–1231.
- Ascierto PA, Dréno B, Larkin J, et al. 5-Year Outcomes with Cobimetinib plus Vemurafenib in Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study. Clin Cancer Res. 2021 [Epub ahead of print].
- Robert C, Grob JJ, Stroyakovskiy D, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. N Engl J Med. 2019; 381(7): 626–636.
- Ascierto PA, Dummer R, Gogas HJ, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. Eur J Cancer. 2020; 126: 33–44.
- Schreuer M, Jansen Y, Planken S, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol. 2017; 18(4): 464–472.
- Valpione S, Carlino M, Mangana J, et al. Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study. J Clin Oncol. 2017; 35(15_suppl): 9512–9512.
- Cybulska-Stopa B, Rogala P, Czarnecka AM, et al. BRAF and MEK inhibitors rechallenge as effective treatment for patients with metastatic melanoma. Melanoma Res. 2020; 30(5): 465–471.
- Czarnecka AM, Teterycz P, Mariuk-Jarema A, et al. Treatment Sequencing and Clinical Outcomes in BRAF-Positive and BRAF-Negative Unresectable and Metastatic Melanoma Patients Treated with New Systemic Therapies in Routine Practice. Target Oncol. 2019; 14(6): 729–742.
- Keilholz U, Ascierto PA, Dummer R, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020; 31(11): 1435–1448.
- Hauschild A, Dummer R, Schadendorf D, et al. Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected V600-Mutant Stage III Melanoma. J Clin Oncol. 2018; 36(35): 3441–3449.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019; 381(16): 1535–1546.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022; 40(2): 127–137.